ANI Pharmaceuticals ANIP Brand royalties and other revenues — Net Revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's brand royalties and other revenues — net revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's brand royalties and other revenues — net revenues?
- ANI Pharmaceuticals (ANIP) reported brand royalties and other revenues — net revenues of $21.54M in Q1 2026.
- What does brand royalties and other revenues — net revenues mean?
- This metric represents the net revenue generated from licensing intellectual property, brand royalties, and ancillary service agreements associated with established pharmaceutical products. It captures income streams derived from the commercialization of legacy brands or partnerships where the company does not directly manage the primary manufacturing or distribution. This revenue segment provides insight into the company's ability to monetize its portfolio through passive or contractual arrangements rather than direct product sales.